Nordson Corp (NASDAQ:NDSN)
Producers of precision dispensing equipment that apply adhesives, sealants and coatings to a broad range of consumer and industrial products during manufacturing operations, helping customers meet quality, productivity and environmental targets.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Bryan Hinmon
Recs
Result of my fundamental-quality screen: high dividend yield, high ROE, some insider ownership, consistently high CAPS rating (4-5 stars over three years).
Recs
valueline rank = 1
Recs
Strong fundamentals. Low debt. Great cash flow.
Recs
Orders are up this quarter in the US and from around the world for the rest of the year at 25% and beyond.
Recs
Good financials and no debt make this a good buy at the bottom of the latest downturn.
Recs
big stuff
Recs
Recs
Performance will exceed expectations. A week dollar coupled with emerging, and expanding, international markets will continue to fuel growth.
Recs
New centers opening for conglomerate outlets (various names) will allow both tax write-off and inflow of cash.
Recs
its on the rise but for how long?
Recs
Good industry. Solid if unglamorous company. Good growth over last 12 months.
Recs
Great dividend paying company that is also growing in revenue and earnings for the long term
Recs
Unique product sector expanding into Europe and thereby benefitting from the strong Euro.
Recs
I came across this recently and am very positive on this stock. I think recent sell offs make for an attractive entry point.
On a EV/EBITDA basis these guys are trading below their 5 yr and 10yr average ranges. In addition, their latest acquisition helps them move into the higher growth/more volatile High Technology industry which while still tempered by their traditional businesses earns the co an overall higher multiple.
I believe the noise related to the inventory step up charges etc has been overblow and if the non-recuriings are backed out this stock begins to look cheaper. the deal is overall accretive and markets seem to be overreacting to the .12-.14 cents of step-up charges which were above their initial estimates. On a cash eps basis - the deal is already accretive.
I like their mix and i think risk is somewhat hedged across the portfolio - its still an economy dependent stock but these guys are primed to benefit from larger trends (buying of plasmas etc) but since they are a few steps down the food chain they havent received that premium valuation. I'm buying this stock farily agressively at these levels and have at PT of $60.
Recs
High ROE. Zack's pick.
Recs
boring company. solid, consistent results.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 17 of 17